Skip to main content
SpringerLink
Log in

Use of Eudragit RS PO, HPMC K100M, Ethyl Cellulose, and Their Combination for Controlling Nicorandil Release from the Bilayer Tablets with Atorvastatin as an Immediate-Release Layer

  • Original Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Purpose

To develop a bilayer tablet containing sustained-release (SR) nicorandil and immediate-release (IR) atorvastatin components in separate layers for the effective treatment of angina accompanied by hyperlipidemia with less dosing frequency and improved patient compliance.

Methods

Sustained-release nicorandil layer was formulated using HPMC K100M with or without Eudragit RS PO and Ethyl Cellulose 10FP. An immediate-release atorvastatin layer was developed using crospovidone and sodium carbonate. The formulations were optimized using a central composite design with the help of Design Expert software. The bilayer tablets were manufactured using a double-compression technique. Dissolution test study was conducted using three different media (pH 1.2, 4.5, and pH 6.8 buffers). Dissolution profiles were analyzed through model-dependent and model-independent methods using DDSolver, an Excel-based add-in program. Selected formulations were subjected to accelerated stability study according to ICH guidelines.

Results

The bilayer tablets were successfully developed with desired quality attributes. Nicorandil release kinetics followed anomalous diffusion, and in vitro release profile was best expressed through the Higuchi equation, while atorvastatin release exhibited Weibull kinetics. The shelf-life of optimized formulations was found to be about 13 months.

Conclusion

The combination of ethyl cellulose and HPMC K100M successfully controlled the release of nicorandil from the bilayer tablet containing immediate-release atorvastatin. The formulation can be subjected to pharmacokinetic studies and clinical trials in the future for better management of cardiovascular diseases and enhancing patient compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Fu Q, Su X, Hou Y, Li M, Li J, Sun J, et al. Once-daily amoxicillin immediate-and extended-release bilayer tablets. Powder Technol. 2016;301:405–11.

    Article  CAS  Google Scholar 

  2. Akseli I, Abebe A, Sprockel O, Cuitiño AM. Mechanistic characterization of bilayer tablet formulations. Powder Technol. 2013;236:30–6.

    Article  CAS  Google Scholar 

  3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33(13):1635–701.

    Article  CAS  PubMed  Google Scholar 

  4. Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial Therapy for Hypertension. Drugs. 2009;69(13):1761–76.

    Article  CAS  PubMed  Google Scholar 

  5. Henderson RA, O'Flynn N. Management of stable angina: summary of NICE guidance. Heart. 2012;98(6):500–7.

    Article  CAS  PubMed  Google Scholar 

  6. Chang L, Li L, Zhang M, Ming-ke N. The myocardial protection of nicorandil plus atorvastatin treatment during percutaneous coronary intervention (PCI). Chinese Journal of Hospital Pharmacy. 2012;21:019.

    Google Scholar 

  7. Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ, Bouthier J, et al. Pharmacokinetics of nicorandil. Am J Cardiol. 1989;63(21):J25–33.

    Article  Google Scholar 

  8. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol. 1989;63(21):J61–J5.

    Article  Google Scholar 

  9. Bravo SA, Lamas MC, Salomón CJ. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Pharm Sci. 2002;5(3):213–9.

    CAS  PubMed  Google Scholar 

  10. Mehta KA, Kislalioglu M, Phuapradit W, Malick A, Shah N. Release performance of a poorly soluble drug from a novel, Eudragit®-based multi-unit erosion matrix. Int J Pharm. 2001;213(1):7–12.

    Article  CAS  PubMed  Google Scholar 

  11. Chithaluru K, Tadikonda R, Gollapudi R, Kandula KKK. Formulation and invitro evaluation of sustained release matrix tablets of losartan potassium. Cellulose. 2011;1200:200.

    Google Scholar 

  12. Lakade S, Bhalekar M. Formulation and evaluation of sustained release matrix tablet of anti-anginal drug, influence of combination of hydrophobic and hydrophlic matrix former. Pharm Technol. 2008;1(4):410–3.

    CAS  Google Scholar 

  13. Kasu RRR, Mutalik S, Reddy S. Correction to: Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS PharmSciTech. 2020;21(5):197.

    Article  PubMed  Google Scholar 

  14. Reza MS, Quadir MA, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharm Sci. 2003;6(2):282–91.

    CAS  PubMed  Google Scholar 

  15. Tamilvanan S, Venkatesh Babu R, Nappinai A, Sivaramakrishnan G. In vitro and in vivo evaluation of hydrophilic and hydrophobic polymers-based nicorandil-loaded peroral tablet compared with its once-daily commercial sustained-release tablet. Drug Dev Ind Pharm. 2011;37(4):436–45.

    Article  CAS  PubMed  Google Scholar 

  16. Patil A, Pohane A, Darbar R, Koutika S, Pothanganti A. Formulation and evaluation of sustained release matrix tablets of Nicorandil. Int J Appl Biol Pharm Technol. 2011;2(3):242–6.

    Google Scholar 

  17. Iffat WSM, Yousuf RI. Hydrophillic and Hydrophobic Polymer Combination: Formulation Development and Optimatization of Nicorandil Sustained Release Tablet. Lat Am J Pharm. 2017;36(5):907–17.

    CAS  Google Scholar 

  18. Ahjel SW, Lupuleasa D. Enhancement of solubility and dissolution rate of different forms of atorvastatin calcium in direct compression tablet formulas. Farmacia. 2009;57:290–300.

    CAS  Google Scholar 

  19. Mukharya A, Chaudhary S, Patel N, Mansuri N, Kumar A. Stable and bio-equivalent formulation of HMG-CoA reductase inhibitor: Atorvastatin Calcium. Int J Pharm Sci Lett. 2011;2(1):12–20.

    Google Scholar 

  20. Solanki UMDD, Bhimani BB, Patel G, Patel UP, Shah RJ. Formulation and evaluation of bilayer gastro retentive drug delivery system of nicorandil. Int J Health Pharm Sci. 2013;2(1):33–43.

    Google Scholar 

  21. Bashir S, Sherwani M, Shabbir I, Batool A. Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia. J Ayub Med Coll Abbottabad. 2011;23(3):97–100.

  22. USP 35 NF 30: United States Pharmacopeial Convention Rockville (MD). 2012;868–70.

  23. Rashid A, Ahmad M, Tulain UR, Iqbal FM. Fabrication and evaluation of 2-hydroxyethyl methacrylate-co-acrylic acid hydrogels for sustained nicorandil delivery. Trop J Pharm Res. 2015;14(7):1121–8.

    Article  CAS  Google Scholar 

  24. Carstensen J. Stability of solids and solid dosage forms. J Pharm Sci. 1974;63(1):1–14.

    Article  CAS  PubMed  Google Scholar 

  25. Rawlins E. Bentley’s textbook of pharmaceutics. London. England: Cassell and Collier MacMillan; 1977.

    Google Scholar 

  26. Frampton JE, Buckley MM, Fitton A. Nicorandil. Drugs. 1992;44(4):625–55.

    Article  CAS  PubMed  Google Scholar 

  27. Andersson K. Clinical pharmacology of potassium channel openers. Pharmacol Toxicol. 1984;70:411.

    Google Scholar 

  28. Mirani AG, Patravale VB. Design of experiments: basic concepts and its application in pharmaceutical product development. In: Pharmaceutical Product Development. Boca Raton: CRC Press; 2016. p. 130–175.

  29. Ahmed FR, Shoaib MH, Yousuf RI, Ali T, Geckeler KE, Siddiqui F, et al. Clay nanotubes as a novel multifunctional excipient for the development of directly compressible diclofenac potassium tablets in a SeDeM driven QbD environment. Eur J Pharm Sci. 2019;133:214–27.

  30. Capece M, Huang Z, Dave R. Insight into a novel strategy for the design of tablet formulations intended for direct compression. J Pharm Sci. 2017;106(6):1608–17.

  31. Cao Q-R, Choi Y-W, Cui J-H, Lee B-J. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. J Control Release. 2005;108(2):351–61.

    Article  CAS  PubMed  Google Scholar 

  32. Rahim N, Naqvi SBS, Bibi R, Iffat W, Shakeel S, Muhammad IN. Disintegrants combination: Development and optimization of a cefadroxil fast disintegrating tablet. Pak J Pharm Sci. 2014;27(5 Spec no):1467–75.

    CAS  PubMed  Google Scholar 

  33. Shirsand S, Suresh S, Swamy P, Para M, Kumar DN. Formulation design of fast disintegrating tablets using disintegrant blends. Indian J Pharm Sci. 2010;72(1):130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Iffat WSM, Yousuf RI, Rahim N, Sultana A, Maboos M. Application and validation of analytical method for simultaneous determination of nicorandil and atorvastatin in bulk and tablet formulations. Lat Am J Pharm. 2018;37(8):1510–6.

    CAS  Google Scholar 

  35. Pharmacopoeia J. Society of Japanese Pharmacopoeia. Amended Chapters. 2007;35(35.2):7.

    Google Scholar 

  36. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263–71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008;364(2):328–43.

    Article  CAS  PubMed  Google Scholar 

  38. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35.

    Article  CAS  Google Scholar 

  39. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharaceutical Sci. 2001;13(2):123–33.

    Article  CAS  Google Scholar 

  40. Shoaib MH, Siddiqi SAS, Yousuf RI, Zaheer K, Hanif M, Rehana S, et al. Development and evaluation of hydrophilic colloid matrix of famotidine tablets. AAPS PharmSciTech. 2010;11(2):708–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20(6):64–74.

    Google Scholar 

  42. Anderson N, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm Biomed Anal. 1998;17(4):811–22.

    Article  CAS  PubMed  Google Scholar 

  43. ICH, Draft Revised Guidance. “Stability testing of new drug substances and products Q1A (R2).” In: Proceedings of the International Conference on Harmonization. Geneva, Switzerland. 2003.

  44. Krishna SRDM. Formulation, optimization and in-vitro charcterization of the sustained release matrix tablets of nicorandil. Int J CurrResChemPharmaSci. 2014;1(10):22–44.

    Google Scholar 

  45. Pharmacopoeia B, Commission BP. 2013.

    Google Scholar 

  46. Jain SP, Mehta DC, Shah SP, Singh PP, Amin PD. Melt-in-mouth pellets of fexofenadine hydrochloride using crospovidone as an extrusion–spheronisation aid. AAPS PharmSciTech. 2010;11(2):917–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Perissutti B, Rubessa F, Moneghini M, Voinovich D. Formulation design of carbamazepine fast-release tablets prepared by melt granulation technique. Int J Pharm. 2003;256(1):53–63.

    Article  CAS  PubMed  Google Scholar 

  48. Patil C, Das S. Effect of various superdisintegrants on the drug release profile and disintegration time of Lamotrigine orally disintegrating tablets. Afr J Pharm Pharmacol. 2009;5(1):76–82.

    Article  Google Scholar 

  49. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech. 2003;4(3):18–23.

    Article  PubMed Central  Google Scholar 

  50. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–23.

    CAS  PubMed  Google Scholar 

  51. Prajapati G, Patel R. Design and in vitro evaluation of novel nicorandil sustained release matrix tablets based on combination of hydrophillic and hydrophobic matrix systems. Int J Pharm Sci Rev Res. 2010;1:33–5.

    CAS  Google Scholar 

  52. Wadher KJ, Kakde RB, Umekar MJ. Study on sustained-release metformin hydrochloride from matrix tablet: influence of hydrophilic polymers and in vitro evaluation. Int J Pharm Investig. 2011;1(3):157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mohapatra S, Kar RK, Sahoo SK. Goodness of fit Model dependent approaches of controlled release matrix tablets of zidovudine. Indian J Pharm Educ Res. 2016;50(1):138–45.

    Article  CAS  Google Scholar 

  54. Aksu B, Yurdasiper A, Ege MA, Karasulu HY. Development and comparative evaluation of extended release indomethacin capsules. Afr J Pharm Pharmacol. 2013;7(30):2201–9.

    Google Scholar 

  55. Pahade MA, Jadhav V, Kadam V. Formulation and development of sustained release matrix tablet of nicorandil. Int J Pharm Sci Rev Res. 2010;4(1):107–11.

    CAS  Google Scholar 

  56. Popy FA, Dewan I, Parvin MN, Islam SA. Evaluation of in vitro equivalence for tablets containing the poorly water-soluble compound atorvastatin. Dissolution Technologies. 2012;19(4):30–3.

    Article  CAS  Google Scholar 

  57. Iffat W, Shoaib MH, Rahim N, Arshad M, Anwer S, Maboos M, et al. Assessment of pharmaceutical equivalence of different generic atorvastatin tablets available in pakistan. Lat Am J Pharm. 2017;36(10):2098–104.

    CAS  Google Scholar 

  58. Hooper D, Clarke F, Mitchell J, Snowden M. A modern approach to the Heckel Equation: The effect of compaction pressure on the yield pressure of ibuprofen and its sodium salt. J Nanomed Nanotechnol. 2016;7(381):2.

    Google Scholar 

  59. Gaikwad SS, Chafle SA, Morris PS, Avari JG. Development and evaluation of bilayer tablets of combination of antibiotics for the treatment of sexually transmitted disease. Brazilian J Pharm Sci. 2016;52(3):555–66.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan

    Wajiha Iffat, Zafar Alam Mahmood, Iyad Naeem Muhammad, Kamran Ahmed, Farrukh Rafiq Ahmed & Muhammad Suleman Imtiaz

  2. Department of Pharmaceutics, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Sind, 75270, Pakistan

    Wajiha Iffat

  3. Department of Pharmaceutics and Bioavailability and Bioequivalence Research Facility, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan

    Muhammad Harris Shoaib, Rabia Ismail Yousuf & Faaiza Qazi

Authors
  1. Wajiha Iffat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Harris Shoaib
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rabia Ismail Yousuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Faaiza Qazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zafar Alam Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Iyad Naeem Muhammad
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kamran Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Farrukh Rafiq Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Muhammad Suleman Imtiaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Harris Shoaib.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Figure S1:

FT-IR spectrum of (a) Nicorandil Standard (b) HPMC K100M- EUDRAGIT RS PO® Combination (c) HPMC K100M-EC combination (d) Atorvastatin Standard (e) Atorvastatin optimized formulation (f) Bilayer Tablet containing HPMC K100M-EUDRAGIT RS PO® Combination (g) Bilayer tablet containing HPMC K100M-EC10FP Combination (PNG 375 kb)

High resolution image (TIF 1612 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iffat, W., Shoaib, M.H., Yousuf, R.I. et al. Use of Eudragit RS PO, HPMC K100M, Ethyl Cellulose, and Their Combination for Controlling Nicorandil Release from the Bilayer Tablets with Atorvastatin as an Immediate-Release Layer. J Pharm Innov 17, 429–448 (2022). https://doi.org/10.1007/s12247-020-09513-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-020-09513-6

Keywords

Search

Navigation